As of June 1, 2023, Angion Biomedica Corp. was acquired by Elicio Therapeutics, Inc., in a reverse merger transaction. Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.
Metrics to compare | ANGN | Peers Peers - average of corresponding metrics from companies closely matching ANGN: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipANGNPeersSector |
---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | 0.0x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price / Book | 0.0x | 0.0x | 0.0x | |
Price / LTM Sales | 0.0x | 0.0x | 0.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 0.0% | |
Fair Value Upside | Unlock | 0.0% | 0.0% | Unlock |